Biocure Technology Inc.
CUREX
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -89.65% | 2,091.67% | -88.78% | -99.79% | -77.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -89.65% | 2,091.67% | -88.78% | -99.79% | -77.09% |
| Operating Income | 89.65% | -2,091.67% | 88.78% | 99.79% | 77.09% |
| Income Before Tax | 86.38% | -413.64% | -5.44% | 75.00% | 94.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.38% | -413.64% | -5.44% | 75.00% | 94.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.38% | -413.64% | -5.44% | 75.00% | 94.92% |
| EBIT | 89.65% | -2,091.67% | 88.78% | 99.79% | 77.09% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 93.01% | -2,000.00% | 7.14% | 76.47% | 95.61% |
| Normalized Basic EPS | 93.33% | -1,200.00% | 11.11% | 72.73% | 79.36% |
| EPS Diluted | 93.01% | -2,000.00% | 7.14% | 76.47% | 95.61% |
| Normalized Diluted EPS | 93.33% | -1,200.00% | 11.11% | 72.73% | 79.36% |
| Average Basic Shares Outstanding | 93.94% | -80.26% | 16.31% | 0.00% | 15.43% |
| Average Diluted Shares Outstanding | 93.94% | -80.26% | 16.31% | 0.00% | 15.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |